CVS Health Corporation — CVS
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $79.33 | $100.70B | 208.8 | 11.1 | 39.6% | 5.2% | $2.66 3.4% | 1.4 |
Latest Headlines
- · BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS)
- · Earnings Preview: What To Expect From CVS Health's Report
- · CVS Health Foundation Grants the American Diabetes Association $2.6 Million to Expand Maternal Diabetes Program Across Two Additional NYC Communities
- · Could CVS Health Corporation's (NYSE:CVS) Weak Financials Mean That The Market Could Correct Its Share Price?
- · Cardinal Health Stock Jumps on Guidance Raise. Why 2026 Will Be a Good Year.
- · Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $268.7B | $7.2B | $5.48 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $292.1B | $8.0B | $6.00 | 8.7% | 11.5% | 9.5% |
| 2 | 2022-12-31 | $322.5B | $4.3B | $3.29 | 10.4% | -46.1% | -45.2% |
| 3 | 2023-12-31 | $357.8B | $8.3B | $6.49 | 10.9% | 93.6% | 97.3% |
| 4 | 2024-12-31 | $372.8B | $4.6B | $3.67 | 4.2% | -44.7% | -43.5% |
| 5 | TTM 2025-03-31 | $379.0B | $5.3B | $4.19 | 1.6% | 14.4% | 14.2% |
| 6 | Average | 7.2% | 5.7% | 6.5% |
EPS
Forecasts
Y/Y % Change
CVS Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 8.7% | 10.4% | 10.9% | 4.2% | 7.1% | 1.1% | 7.1% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 7 | 7 | |
| EPS Growth (%) | 11.5% | -46.1% | 93.6% | -44.7% | 83.0% | 7.5% | 17.5% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 10 | 10 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | Facilities / D&A ($) |
|---|---|---|---|
| 2021 | $292.1B | $235.5B | $4.5B |
| 2022 | $322.5B | $263.7B | $4.2B |
| 2023 | $357.8B | $299.0B | $4.4B |
| 2024 | $372.8B | $316.8B | $4.6B |
| TTM | $394.1B | $334.8B | $4.6B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|
| 2022 | 10.39 | 11.99 | -5.84 |
| 2023 | 10.95 | 13.36 | 3.36 |
| 2024 | 4.20 | 5.96 | 5.29 |
| TTM | 5.71 | 5.67 | 0.20 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $258,343M |
| 1 | Cash | $11,787M |
| 2 | Total Liabilities | $180,792M |
| 3 | Total Debt | $82,724M |
| 4 | Total Equity | $77,379M |
| 5 | Debt to Equity Ratio | 1.07 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $79.33 | 4.1% | Nicks Growth: 5% Nick's Expected Margin: 2% FINVIZ Growth: 15% |
Nicks: 11 Finviz: 28 |
Nick's: 0.218 | 0.3 | 208.8 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $0.38 EPS | TTM | $4.14 | -94.8% | $10.45 | -86.8% |
| $6.65 EPS | 2025 | $72.45 | -8.7% | $182.95 | 130.6% |
| $7.15 EPS | 2026 | $77.89 | -1.8% | $196.71 | 148.0% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 20.16% | 5.29% | 11.88% | 5.37% | 13.58% | 0.75% | 39.91% | 5.36% | 99.3% | 48.7% |
| 3 Years | 20.16% | 5.29% | 11.88% | 5.37% | 13.58% | 0.75% | 39.91% | 5.36% | 99.3% | 48.7% |
| 5 Years | 20.16% | 5.29% | 11.88% | 5.37% | 13.58% | 0.75% | 39.91% | 5.36% | 99.3% | 48.7% |
| 10 Years | 20.16% | 5.29% | 11.88% | 5.37% | 13.58% | 0.75% | 39.91% | 5.36% | 99.3% | 48.7% |